Back to Search Start Over

Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study.

Authors :
Bulathsinhala L
Eleangovan N
Heaney LG
Menzies-Gow A
Gibson PG
Peters M
Hew M
van Boven JFM
Lehtimäki L
van Ganse E
Belhassen M
Harvey ES
Perez de Llano L
Maitland-van der Zee AH
Papadopoulos NG
FitzGerald JM
Porsbjerg C
Canonica GW
Backer V
Rhee CK
Verhamme KMC
Buhl R
Cosio BG
Carter V
Price C
Le T
Stagno d'Alcontres M
Gopalan G
Tran TN
Price D
Source :
The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2019 Feb; Vol. 7 (2), pp. 578-588.e2. Date of Electronic Publication: 2018 Sep 01.
Publication Year :
2019

Abstract

Background: The lack of centralized data on severe asthma has resulted in a scarcity of information about the disease and its management. The development of a common data collection tool for the International Severe Asthma Registry (ISAR) will enable standardized data collection, subsequently enabling data interoperability.<br />Objectives: To create a standardized list of variables for the first international registry for severe asthma via expert consensus.<br />Methods: A modified Delphi process was used to reach consensus on a minimum set of variables to capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the field of severe asthma research. The process consisted of 3 iterative rounds. In each round, all Delphi panel members were issued an electronic ISAR Delphi workbook to complete and return to the ISAR Delphi administrator. Workbooks and result summaries were anonymously distributed by the Delphi administrator to all panel members at subsequent rounds. Finalization of the core variable list was facilitated by 2 face-to-face meetings.<br />Results: Of the initial 747 selected variables, the Delphi panel reached a consensus on 95. The chosen variables will allow severe asthma to be assessed against patient demographics and medical history, patient-reported outcomes, diagnostic information, and clinical characteristics. Physician-reported outcomes such as nonadherence and information about treatment and management strategies will also be recorded.<br />Conclusions: This is the first global attempt to generate an ISAR using a common set of core variables to ensure that data collected across all participating countries are standardized.<br /> (Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
2213-2201
Volume :
7
Issue :
2
Database :
MEDLINE
Journal :
The journal of allergy and clinical immunology. In practice
Publication Type :
Academic Journal
Accession number :
30179741
Full Text :
https://doi.org/10.1016/j.jaip.2018.08.016